TABLE 1.
Clinical and demographic data
| Characteristics | All patients (n=80) % | NLR <2.8 (n=47) % | NLR ≥2.8 (n=33) % | p |
|---|---|---|---|---|
| Gender | 0.894 | |||
| Male | 32.5 | 31.9 | 33.3 | |
| Female | 67.5 | 68.1 | 66.7 | |
| Age (Year) | ||||
| Median (Min–max) | 55 (26–77) | 58 (32–77) | 52 (26–74) | 0.028 |
| HT | ||||
| Yes | 15.0 | 17.0 | 12.1 | 0.752 |
| DM | ||||
| Yes | 3.8 | 6.4 | 0.0 | 0.264 |
| CIHD | ||||
| Yes | 2.5 | 2.2 | 3.0 | 0.664 |
| COPD | ||||
| Yes | 5.0 | 8.5 | 0.0 | 0.139 |
| Smoking | ||||
| Yes | 26.3 | 27.7 | 24.2 | 0.732 |
| Dysphagia | ||||
| Yes | 93.8 | 93.6 | 93.9 | 0.953 |
| Abdominal pain | ||||
| Yes | 12.5 | 8.5 | 18.2 | 0.304 |
| Weight loss | ||||
| Yes | 23.8 | 29.8 | 15.2 | 0.130 |
| Obstruction | ||||
| Yes | 13.8 | 12.8 | 15.2 | 0.754 |
| ECOG-PS | 0.391 | |||
| 0–1 | 73.8 | 70.2 | 78.8 | |
| 2 | 26.3 | 29.8 | 21.2 | |
| Localization | 0.585 | |||
| Middle 2/3 | 72.5 | 70.2 | 75.8 | |
| Lower 1/3 | 27.5 | 29.8 | 24.2 | |
| Grade | 0.137 | |||
| 1+2 | 82.5 | 76.6 | 90.9 | |
| 3 | 17.5 | 23.4 | 9.1 | |
| Neoadjuvant | ||||
| Yes | 40.0 | 40.4 | 39.4 | 0.926 |
| Stage | 0.149 | |||
| I+II | 75.0 | 80.9 | 66.7 | |
| III | 25.0 | 19.1 | 33.3 | |
| Adjuvant treatment | 0.012 | |||
| Yes | 13.2 | 4.7 | 24.2 | |
| Recurrence | ||||
| Yes | 28.8 | 17.0 | 45.5 | 0.006 |
| Site of recurrence | ||||
| Locoregional | 30.4 | 0.0 | 46.7 | 0.040 |
| Lung | 8.7 | 0.0 | 13.3 | |
| Liver | 26.1 | 50.0 | 13.3 | |
| Distant LN | 34.8 | 50.0 | 26.7 | |
| Final status | 0.011 | |||
| Dead | 32.5 | 21.3 | 48.5 | |
| Alive | 67.5 | 78.7 | 51.5 |
CIHD: Chronic ischemic heart disease; DM: Diabetes mellitus; ECOG-PS: Eastern Cooperative Oncology Group Performance Score; HT: Hypertension; LN: Lymph node.